Marksans Pharma Limited — PPTs, 05-02-2026: Investor Presentation

Marksans Pharma delivered a stable Q3 FY26! Operating revenue rose 10.6% YoY to ₹ 754 Cr, fueled by strong US & UK market demand, especially seasonal cough/cold. EBITDA jumped 23.2% YoY to ₹ 161 Cr, with margins hitting 21.3% thanks to lower raw material costs and better product mix. Net Profit grew 8.2% YoY to ₹ 114 Cr. For 9M FY26, revenue hit ₹ 2,095 Cr (+9.4% YoY).

Growth strategy focuses on expanding the huge OTC market, a robust R&D pipeline (100+ products), and doubling India's manufacturing capacity. Recent moves include new European & Canadian subsidiaries and key product approvals. Management aims for ₹ 3,000 Cr revenue soon, doubling US business, and cracking the top 3 Indian pharma firms in the UK. Cash balance is solid at ₹ 824.2 Cr.